Editorial
The Rise and Fall of Vancomycin
Since its development in the 1950s, vancomycin has had a prominent role in the treatment of staphylococcal infections. Soon after its debut, the first cases of methicillin-resistant Staphylococcus aureus (MRSA) were reported (1961),1 but remained a rarity until the late 1970s.2